Esphera SynBio develops cancer immunotherapies, vaccines, and immunomodulatory therapies using synthetic biology to engineer exosomes as nanomedicines.

Actym Therapeutics develops a new drug modality using genetically modified bacteria to initiate a selective immune response within the tumor microenvironment for treating solid tumors.